INS and type 2 diabetes mellitus: Although clinical trials to investigate the effects of luseogliflozin in patients with T2D classified by endogenous insulin secretion are needed, our findings suggest that luseogliflozin has more potential for the treatment of diabetes and related disorders than currently expected in clinical practice.